Skip to main content Accessibility help
×
Home
Hostname: page-component-55b6f6c457-xklcj Total loading time: 0.245 Render date: 2021-09-23T23:39:19.549Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Article contents

EPA-1719 – Effectiveness of Switching to Agomelatine in Antidepressant-related Sexual Dysfunction

Published online by Cambridge University Press:  15 April 2020

A.L. Montejo
Affiliation:
Psychiatry Dpt., Hospital Universitario de Salamanca. Universidad de Salamanca. IBSAL., Salamanca, Spain
A. Perez Urdaniz
Affiliation:
Psychiatry Dpt., Hospital Universitario de Salamanca. Universidad de Salamanca, Salamanca, Spain
I. Mosqueira
Affiliation:
Psychiatry Dpt., Hospital Universitario de Salamanca., Salamanca, Spain
N. Prieto
Affiliation:
Psychiatry Dpt., Hospital Universitario de Salamanca. IBSAL, Salamanca, Spain
A. De la Rica
Affiliation:
Psychiatry Dpt., Hospital Universitario de Salamanca, Salamanca, Spain
M.T. Gallego
Affiliation:
Psychiatry Dpt., Hospital Universitario de Salamanca. IBSAL, Salamanca, Spain
S. Majadas
Affiliation:
Neuroscience Group., Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
Get access

Abstract

Introduction

Antidepressants such as SSRI and SNRI are associated to sexual dysfunction (SD). Agomelatine, an antidepressant with an unique and different mechanism of action, didn’t produce SD in patients and healthy volunteeers (Montejo et al, 2010).

Objective

To evaluate the effectiveness of switching to agomelatine in patient's experiencing SD related to previous antidepressant treatment (AD-SD).

Methods

Observational prospective study of 2-6 months follow-up. Adult sexually active patients presenting AD-SD and switched to agomelatine monotherapy were included. SD was evaluated with the change at endpoint in the validated and specific questionnaire PR-Sex-DQ-SALSEX (Montejo et al, 2001).

Results

51 patients were included. All of them presented moderate to severe SD at inclusion. Previous AD treatment was an SSRI (63.4%) or SNRI (36.6%). Mean time of follow-up was 10.38 weeks (Sd: 5.20). Mean dose of agometine was 28.43 mg/day (Sd: 10.02). Sexual dysfunction (sexual interest, orgasm delay, anorgasmia and arousal problems) improved after switching to agomelatine, as shown by the significant reduction in PR-Sex-DQ-SALSEX score (global and by items) at endpoint (p<0.001, Wilcoxon test). At endpoint 44.9% of the sample had resolved their SD. Moderate-severe SD was present only in 18.4%. 13.9% discontinued agomelatine due to lack of efficacy and 9.7% because tolerability issues, specially associated to discontinuation syndrome.

Conclusions

In our sample global and every domain of SD improved significantly after switching to agomelatine, what makes it an apparent successful option to manage Antidepressant-related Sexual Dysfunction. A gradual switching is suggested in order to avoid treatment failure due to discontinuation syndrome.

Type
E05 - e-Poster Oral Session 05: Childhood and Geriatry, Depression
Copyright
Copyright © European Psychiatric Association 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Submit a response

Comments

No Comments have been published for this article.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

EPA-1719 – Effectiveness of Switching to Agomelatine in Antidepressant-related Sexual Dysfunction
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

EPA-1719 – Effectiveness of Switching to Agomelatine in Antidepressant-related Sexual Dysfunction
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

EPA-1719 – Effectiveness of Switching to Agomelatine in Antidepressant-related Sexual Dysfunction
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *